The global small molecule API market size was valued at USD 206.9 billion in 2025 and is predicted to hit around USD 374.03 ...

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles.Phase IIb data ...

编者按：随着研发技术的不断进步，新一代共价药物的开发已成为业界高度关注的方向。截至目前，已有超过50种共价药物成功获批上市，并在多个疾病领域展现出显著疗效。值得关注的是，新一代共价药物正不断突破局限，向可逆性共价结合及靶向半胱氨酸以外氨基酸残基的方向 ...

Dr. Koneru has extensive experience and expertise in the field of drug development with a track record of advancing novel therapeutics from early development through later-stage clinical programs. She ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

Tv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

In opposing a fix to the 2022 Inflation Reduction Act, a leading voice in the effort to move the U.S. biopharmaceutical system toward European-style price controls cited “complicated details” in his ...

Key established manufacturers continue to hold significant market influence due to their extensive production capacities, R&D ...